TCT 2025: REC-CAGEFREE I Trial Compares Drug-Coated Balloons and Drug-Eluting Stents
The REC-CAGEFREE I trial was presented at the TCT Conference 2025 in San Francisco, USA, by Dr. Yuehao Lv.
The trial found that drug-coated balloons (DCBs) were associated with a higher risk of device-oriented composite events (DoCE) compared to drug-eluting stents (DES) in patients with long de novo coronary artery lesions.
However, outcomes were comparable for shorter lesions.
The findings were presented by Dr. Yuehao Lv on behalf of the REC-CAGEFREE I investigators at TCT 2025.
Author's summary: TCT 2025 presents trial results comparing DCBs and DES.
More News
- Distorted narratives risk reversing South Caucasus peace progress [OPINION]
- How Discrimination and Stress Impact the Mental Health of Young Sexual Minority Men
- Formal Celtic approach could still tempt Kieran McKenna as FOUR manager targets assessed by sources
- Danielle Smith: Balancing the budget gets a lot easier if you build a pipeline
- CNN announces election night coverage plans, including All Access-only ‘livecast’
- Risk of unfairness in historical prosecutions
- Reversing course: Spotsylvania Board of Supervisors reduce recommended data center setbacks - Fredericksburg Free Press
- Shares of Navan Down 16% In Long-Awaited IPO Debut
- NASA Confirms Interstellar Comet 3I/ATLAS on Stable Course, No Threat to Earth
- OPINION – Luke 1: The announcement to Mary